MicroRNA-381 represses ID1 and is deregulated in lung adenocarcinoma

Journal of Thoracic Oncology

Volumn 7, Issue 7, 2012, Pages 1069-1077

  Rothschild, Sacha I ^a,b   Tschan, Mario P ^a,b   Jaggi, Rolf ^a   Fey, Martin F ^b   Gugger, Mathias ^a   Gautschi, Oliver ^a,c  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c LUZERNER KANTONSSPITAL   (Switzerland)

Author keywords

Inhibitor of differentiation protein 1; Lung cancer; MiR 381; Src

Indexed keywords

DASATINIB; INHIBITOR OF DIFFERENTIATION 1; MESSENGER RNA; MICRORNA; MICRORNA 381; SARACATINIB; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ARTICLE; CANCER CELL; CANCER PROGNOSIS; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ASSAY; ENZYME INHIBITION; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; METASTASIS POTENTIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA BINDING; UPREGULATION;

EID: 84862856363     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31824fe976     Document Type: Article

References (57)

1. Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011;6:244-285.
2. Kris MG, Johnson BE, Kwiatkowski DJ, et al. Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC). J Clin Oncol 2011;29:CRA7506.
3. Lovly CM Carbone D P. Lung cancer in 2010: One size does not fit all. Nat Rev Clin Oncol 2011;8:68-70.
4. Maeda R, Yoshida J, Ishii G, Hishida T, Nishimura M, Nagai K. Risk factors for tumor recurrence in patients with early-stage (stage I and II) non-small cell lung cancer: patient selection criteria for adjuvant chemotherapy according to the seventh edition TNM classification. Chest 2011;140:1494-1502.
5. Mitra SK Schlaepfer DD. Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol 2006;18:516-523. (Pubitemid 44332916)
6. Summy JM Gallick GE. Treatment for advanced tumors: SRC reclaims center stage. Clin Cancer Res 2006;12:1398-1401.
7. Rothschild SI, Gautschi O, Haura EB, et al. Src inhibitors in lung cancer: current status and future directions. Clin Lung Cancer 2010;11:238-242.
8. Gautschi O, Tepper CG, Purnell PR, et al. Regulation of Id1 expression by SRC: implications for targeting of the bone morphogenetic protein pathway in cancer. Cancer Res 2008;68:2250-2258. (Pubitemid 351521798)
9. Benezra R, Davis RL, Lockshon D, Turner DL, Weintraub H. The protein Id: a negative regulator of helix-loop-helix DNA binding proteins. Cell 1990;61:49-59.
10. Barone M V, Pepperkok R, Peverali FA, Philipson L. Id proteins control growth induction in mammalian cells. Proc Natl Acad Sci USA 1994;91:4985-4988. (Pubitemid 24177775)
11. Massagué J, Blain S W, Lo RS. TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 2000;103:295-309.
12. Yu X, Xu X, Han B, Zhou R. Inhibitor of DNA binding-1 overexpression in prostate cancer: relevance to tumor differentiation. Pathol Oncol Res 2009;15:91-96.
13. Ouyang XS, Wang X, Ling MT, Wong HL, Tsao S W, Wong YC. Id-1 stimulates serum independent prostate cancer cell proliferation through inactivation of p16(INK4a)/pRB pathway. Carcinogenesis 2002;23:721-725. (Pubitemid 34567509)
14. de Candia P, Solit DB, Giri D, et al. Angiogenesis impairment in Id-deficient mice cooperates with an Hsp90 inhibitor to completely suppress HER2/neu-dependent breast tumors. Proc Natl Acad Sci USA 2003;100:12337-12342. (Pubitemid 37271561)
15. Lyden D, Young AZ, Zagzag D, et al. Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. Nature 1999;401:670-677.
16. Li H, Gerald WL, Benezra R. Utilization of bone marrow-derived endothelial cell precursors in spontaneous prostate tumors varies with tumor grade. Cancer Res 2004;64:6137-6143. (Pubitemid 39129414)
17. Gupta G P, Perk J, Acharyya S, et al. ID genes mediate tumor reinitiation during breast cancer lung metastasis. Proc Natl Acad Sci USA 2007;104:19506-19511.
18. Gao D, Nolan DJ, Mellick AS, Bambino K, McDonnell K, Mittal V. Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science 2008;319:195-198.
19. Fong S, Debs RJ, Desprez PY. Id genes and proteins as promising targets in cancer therapy. Trends Mol Med 2004;10:387-392. (Pubitemid 39061140)
20. Lasorella A, Uo T, Iavarone A. Id proteins at the cross-road of development and cancer. Oncogene 2001;20:8326-8333. (Pubitemid 34121903)
21. Kamalian L, Gosney JR, Forootan SS, et al. Increased expression of Id family proteins in small cell lung cancer and its prognostic significance. Clin Cancer Res 2008;14:2318-2325. (Pubitemid 351551063)
22. Rothschild SI, Kappeler A, Ratschiller D, et al. The stem cell gene "inhibitor of differentiation 1" (ID1) is frequently expressed in non-small cell lung cancer. Lung Cancer 2011;71:306-311.
23. Ponz-Sarvisé M, Nguewa PA, Pajares MJ, et al. Inhibitor of differentiation-1 as a novel prognostic factor in NSCLC patients with adenocarcinoma histology and its potential contribution to therapy resistance. Clin Cancer Res 2011;17:4155-4166.
24. Johnson SM, Grosshans H, Shingara J, et al. RAS is regulated by the let-7 microRNA family. Cell 2005;120:635-647. (Pubitemid 40343076)
25. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007;133:647-658. (Pubitemid 47187346)
26. Valencia-Sanchez MA, Liu J, Hannon GJ, Parker R. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev 2006;20:515-524. (Pubitemid 43345317)
27. Guo H, Ingolia NT, Weissman JS, Bartel D P. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 2010;466:835-840.
28. Lewis B P, Burge CB, Bartel D P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005;120:15-20. (Pubitemid 40094598)
29. Calin GA Croce CM. MicroRNA-cancer connection: the beginning of a new tale. Cancer Res 2006;66:7390-7394. (Pubitemid 44289189)
30. Calin GA, Sevignani C, Dumitru CD, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004;101:2999-3004. (Pubitemid 38327724)
31. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009;10:704-714.
32. Lebanony D, Benjamin H, Gilad S, et al. Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. J Clin Oncol 2009;27:2030-2037.
33. Bishop JA, Benjamin H, Cholakh H, Chajut A, Clark D P, Westra WH. Accurate classification of non-small cell lung carcinoma using a novel microRNA-based approach. Clin Cancer Res 2010;16:610-619.
34. Yu SL, Chen HY, Chang GC, et al. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 2008;13:48-57.
35. Patnaik SK, Kannisto E, Knudsen S, Yendamuri S. Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection. Cancer Res 2010;70:36-45.
36. Takamizawa J, Konishi H, Yanagisawa K, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004;64:3753-3756. (Pubitemid 38697282)
37. Krek A, Grün D, Poy MN, et al. Combinatorial microRNA target predictions. Nat Genet 2005;37:495-500. (Pubitemid 40617277)
38. Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res 2006;34(Database issue):D140-D144.
39. John B, Enright AJ, Aravin A, Tuschl T, Sander C, Marks DS. Human MicroRNA targets. PLoS Biol 2004;2:e363.
40. Oberli A, Popovici V, Delorenzi M, et al. Expression profiling with RNA from formalin-fixed, paraffin-embedded material. BMC Med Genomics 2008;1:9.
41. Livak KJ Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25:402-408. (Pubitemid 34164012)
42. Tschan M P, Fischer KM, Fung VS, et al. Alternative splicing of the human cyclin D-binding Myb-like protein (hDMP1) yields a truncated protein isoform that alters macrophage differentiation patterns. J Biol Chem 2003;278:42750-42760. (Pubitemid 37345884)
43. Albini A Benelli R. The chemoinvasion assay: a method to assess tumor and endothelial cell invasion and its modulation. Nat Protoc 2007;2:504-511. (Pubitemid 47040014)
44. Albini A Benelli R. The chemoinvasion assay: a method to assess tumor and endothelial cell invasion and its modulation. Nat Protoc 2007;2:504-511. (Pubitemid 47040014)
45. Kuhn DE, Martin MM, Feldman DS, Terry AV Jr, Nuovo GJ, Elton TS. Experimental validation of miRNA targets. Methods 2008;44:47-54. (Pubitemid 350297983)
46. Rothschild SI, Tschan M P, Federzoni EA, et al. MicroRNA-29b is involved in the Src-ID1 signaling pathway and is dysregulated in human lung adenocarcinoma. Oncogene January 16, 2012 [Epub ahead of print].
47. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005;435:834-838. (Pubitemid 40839735)
48. Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006;103:2257-2261. (Pubitemid 43271657)
49. Lee YN, Brandal S, Noel P, et al. KIT signaling regulates MITF expression through miRNAs in normal and malignant mast cell proliferation. Blood 2011;117:3629-3640.
50. Khudayberdiev S, Fiore R, Schratt G. MicroRNA as modulators of neuronal responses. Commun Integr Biol 2009;2:411-413.
51. Tang H, Liu X, Wang Z, et al. Interaction of hsa-miR-381 and glioma suppressor LRRC4 is involved in glioma growth. Brain Res 2011;1390:21-32.
52. Jeon HM, Jin X, Lee JS, et al. Inhibitor of differentiation 4 drives brain tumor-initiating cell genesis through cyclin E and notch signaling. Genes Dev 2008;22:2028-2033.
53. Kuzontkoski PM, Mulligan-Kehoe MJ, Harris BT, Israel MA. Inhibitor of DNA binding-4 promotes angiogenesis and growth of glioblastoma multiforme by elevating matrix GLA levels. Oncogene 2010;29:3793-3802.
54. Yun K, Mantani A, Garel S, Rubenstein J, Israel MA. Id4 regulates neural progenitor proliferation and differentiation in vivo. Development 2004;131:5441-5448. (Pubitemid 39562186)
55. Johnson FM, Bekele BN, Feng L, et al. Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 2010;28:4609-4615.
56. Blower PE, Chung JH, Verducci JS, et al. MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer Ther 2008;7:1-9.
57. Blower PE, Verducci JS, Lin S, et al. MicroRNA expression profiles for the NCI-60 cancer cell panel. Mol Cancer Ther 2007;6:1483-1491. (Pubitemid 46954015)